BeOne Medicines
ONC
#651
Rank
HK$278.00 B
Marketcap
HK$2,512
Share price
-2.56%
Change (1 day)
55.53%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeOne Medicines (ONC)

Earnings in 2025 (TTM): HK$1.42 Billion

According to BeOne Medicines's latest financial reports the company's current earnings are HK$4.97 Billion. In 2024 the company made an earning of -HK$4.43 Billion, an increase over its 2023 earnings that were of -HK$9.4 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeOne Medicines from 2015 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) HK$1.42 B-132.32%
2024 -HK$4.43 Billion-52.95%
2023 -HK$9.4 Billion-32.52%
2022 -HK$13.93 Billion24.39%
2021 -HK$11.2 Billion-13.21%
2020 -HK$12.9 Billion72.69%
2019 -HK$7.47 Billion36.01%
2018 -HK$5.5 Billion616.83%
2017 -HK$0.77 Billion-15.24%
2016 -HK$0.91 Billion107.91%
2015 -HK$0.44 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Onconova Therapeutics
ONTX
-HK$0.15 Billion-109.94%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-HK$1.25 Billion-187.30%๐Ÿ‡บ๐Ÿ‡ธ USA